Amneal Pharmaceuticals $2.35 billion term loan
We advised Amneal Pharmaceuticals on a new term loan
Davis Polk advised certain subsidiaries of Amneal Pharmaceuticals Inc. in connection with a new $2.35 billion term loan, the effect of which is to extend the maturity date of an equivalent principal amount of term loans outstanding under Amneal’s existing term loan credit agreement to May 4, 2028.
Amneal Pharmaceuticals is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Amneal has over 270 products and a manufacturing capacity of approximately 20 billion units.
The Davis Polk finance and liability management team included partners Jack Orford, Brian M. Resnick, Michael Kaplan and J.W. Perry and associates Michael Pera, Yuko Sin and Zoe Chen. Partner Michael Mollerus, counsel Leslie J. Altus and associates Michael Mirabella and Bradford Sherman provided tax advice. All members of the Davis Polk team are based in the New York office.